索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]陈建淑 姚亚丽.射血分数中间值心力衰竭的研究进展[J].国际心血管病杂志,2018,06:344-346.
点击复制

射血分数中间值心力衰竭的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年06期
页码:
344-346
栏目:
综述
出版日期:
2019-02-01

文章信息/Info

Title:
-
作者:
陈建淑 姚亚丽
Author(s):
-
关键词:
心力衰竭;  射血分数中间值;  临床特征;  预后
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.06.007
文献标识码:
-
摘要:
射血分数中间值心力衰竭与射血分数保留心力衰竭(HFpEF)和射血分数降低心力衰竭(HFrEF)相比具有独特的临床、超声心动图、血液动力学及预后特征。左室射血分数(LVEF)在心力衰竭病程中可能会发生改变,射血分数中间值心力衰竭可分为LVEF持续维持在40%～49%、HFpEF的LVEF降至中间状态、HFrEF的LVEF升高至中间状态3种类型。该文介绍射血分数中间值心力衰竭及其亚型的人群特点、实验室检查特点、超声心动图表现及预后等方面的研究进展。
Abstract:
-

参考文献/References


[1] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J]. Eur J Heart Fail, 2016, 18(8):891-975.
[2] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [J]. Circulation, 2017, 136(6):e137-e161.
[3] Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes[J]. Circulation, 2014, 129(23):2380-2387.
[4] Howlett JG, Chan M, Ezekowitz JA, et al. The Canadian cardiovascular society heart failure companion: bridging guidelines to your practice[J]. Can J Cardiol, 2016, 32(3):296-310.
[5] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2013, 128(16):1810-1852.
[6] Nadruz W, West E, Santos M, et al. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes[J]. Circ Heart Fail, 2016, 9(4):e002826.
[7] Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction[J]. Circ Heart Fail, 2012, 5(6):720-726.
[8] Clarke CL, Grunwald GK, Allen LA, et al. Natural history of left ventricular ejection fraction in patients with heart failure[J]. Circ Cardiovasc Qual Outcomes, 2013, 6(6):680-686.
[9] Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the medicare population[J]. Am Heart J, 2014, 168(5):721-730.
[10] Postmus D, Van Veldhuisen DJ, Jaarsma T, et al. The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure[J]. Eur J Heart Fail, 2012, 14(2):168-175.
[11] Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction(40-50%)[J]. Eur J Heart Fail, 2014, 16(10):1049-1055.
[12] Faxén UL, Hage C, Benson L, et al. HFpEF and HFrEF display different phenotypes as assessed by IGF-1 and IGFBP-1[J]. J Card Fail, 2017, 23(4):293-303.
[13] Feldman T, Mauri L, Kahwash R, et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction(REDUCE LAP-HF Ⅰ [reduce elevated left atrial pressure in patients with heart failure]): a phase 2, randomized, sham-controlled trial[J]. Circulation, 2018, 137(4):364-375.
[14] Lüscher TF. Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation[J]. Eur Heart J, 2018, 39(1):1-4.
[15] Kapoor JR, Kapoor R, Ju C, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction[J]. JACC Heart Fail, 2016, 4(6):464-472.
[16] Mcgowan JV, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity[J]. Cardiovasc Drugs Ther, 2017, 31(1):63-75.
[17] Loar RW, Noel CV, Tunuguntla H, et al. State of the art review: chemotherapy-induced cardiotoxicity in children[J]. Congenit Heart Dis, 2018, 13(1):5-15.
[18] Rickenbacher P, Kaufmann BA, Maeder MT, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure(TIME-CHF)[J]. Eur J Heart Fail, 2017, 19(12):1586-1596.
[19] Bayés-Genís A, Núñez J, Lupón J. Heart failure with mid-range ejection fraction: a transition phenotype?[J]. Eur J Heart Fail, 2017, 19(12):1635-1637.
[20] Punnoose LR, Givertz MM, Lewis EF, et al. Heart failure with recovered ejection fraction: a distinct clinical entity[J]. J Card Fail, 2011, 17(7):527-532.
[21] He KL, Burkhoff D, Leng WX, et al. Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%[J]. Am J Cardiol, 2009, 103(6):845-851.
[22] Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes[J]. Circulation, 2014, 129(23):2380-2387.
[23] Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The cardiovascular health study[J]. Ann Intern Med, 2002, 137(8):631-639.
[24] Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients[J]. Circulation, 2005, 112(24):3738-3744.

备注/Memo

备注/Memo:
作者单位:730000 兰州大学第一医院心血管内科
通信作者:姚亚丽,Email:yaoyalifs@163.com
更新日期/Last Update: 2018-11-30